HalioDx – Series B, IPO, exit, carve-out
26 January 2022
Inspirit Partners advised HalioDx on Series B, IPO, exit and carve-out.
March 25 2015
HalioDx designs and develops in-vitro diagnostic products in the immuno-oncology field. The company offers a range of immune scoring tests. It offers ImmunoscoreCC, a decision making tool to clinicians for patients management based on anti-tumor immune response. HalioDx was incorporated in 2014 and is based in Marseille, France.